New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:16 EDTCANFCan-Fite BioPharma submits Phase II study protocol with CF102
Can-Fite BioPharma announced that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted. The company plans to conduct the Phase II study in Israel, Europe and the US and will include 78 subjects with second-line treatment of advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. The study will investigate the efficacy and safety of CF102 vs. placebo. The US Food and Drug Administration has granted Orphan Drug designation for CF102, for the treatment of hepatocellular carcinoma. According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2B by 2015.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
08:45 EDTCANFCan-Fite BioPharma CF101 has major catalysts, says Roth Capital
Subscribe for More Information
07:14 EDTCANFCan-Fite BioPharma initiated with a Buy at H.C. Wainwright
Subscribe for More Information
07:08 EDTCANFCan-Fite BioPharma sees announcing data for Phase II/III psoriasis trial in 1Q15
Can-Fite BioPharma announced several upcoming and near-term milestones on its CF101 and CF102 indications for liver cancer, rheumatoid arthritis, psoriasis, glaucoma and the development of a commercial biomarker blood test kit for the A3 adenosine receptor. For Q4, the company is planning Phase III trials for CF101 for rheumatoid arthritis following the release of positive Phase II study results. Also in Q4, for CF102, patient enrollment has commenced for a Phase II trial in Israel, Europe and the U.S. for the treatment of patients with advanced liver cancer as a second line therapy. In 1Q15, for CF101, the company plans to announce data for Phase II/III trial for psoriasis with 300 patients for which Can-Fite has already received positive interim data from the first 100 patients. Also for CF101, in Q2/Q3 2015, the company plans to announce data for the Phase II study for glaucoma with 88 patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use